Bay Area Retina Associates

Walnut Creek, California 94704

6 studies enrolling now · 59 studies all time

What they study most

Age - Related Macular Degeneration (AMD), Age Related Macular Degeneration, Age Related Macular Degeneration (ARMD), Age-Related Macular Degeneration, Age-related Macular Degeneration, Cataract, Central Serous Chorioretinopathy, Choroidal Neovascularization, DME, Diabetes Mellitus, Diabetic Macular Edema, Diabetic Macular Edema (DME)

Studies at this site

• A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD — Recruiting now
• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME — Recruiting now
• Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants — Recruiting now
• Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD — Recruiting now
• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Recruiting now
• Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Recruiting now
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD — Completed
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) — Running, not enrolling
• 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Running, not enrolling
• ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) — Running, not enrolling
• A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
• A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Running, not enrolling
• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Completed
• Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema — Completed
• Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification — Completed
• Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
• Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT) — Completed
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). — Stopped early
• NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME) — Completed
• Safety and Efficacy of AM712 in Patients with NAMD — Completed
• A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A — Completed
• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) — Stopped early
• A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration — Completed
• A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration — Completed
• A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration — Completed
• A Study Assessing AR-13503 Implant in Subjects With nAMD or DME — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD — Completed
• Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy — Completed
• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects — Completed
• Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO — Stopped early
• RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration — Completed
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) — Completed
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
• Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema — Completed
• Treatment for CI-DME in Eyes With Very Good VA Study — Completed
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Evaluation of Vitrectomy for Diabetic Macular Edema — Completed
• Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema — Completed
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early
• Phase II Combination Steroid and Anti-VEGF for Persistent DME — Completed
• Short-Term Oral Mifepristone for Central Serous Chorioretinopathy — Completed